Be Biopharma, Inc. has presented groundbreaking preclinical findings that underscore the potential of Engineered B Cell Medicines (BCMs) as a novel therapeutic avenue for Hypophosphatasia (HPP), a rare genetic disorder. During the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, the company showcased how BCMs, developed using CRISPR/Cas9 precision gene engineering and […]
US based Exonics Therapeutics has secured $5 million seed funding from CureDuchenne Ventures, a subsidiary of nonprofit DMD advocacy group, CureDuchenne to advance its therapy for Duchenne Muscular Dystrophy, a severe form of muscular dystrophy.
Exonics Therapeutics, a biotechnology firm based in Boston, Massachusetts, has secured $5 million in seed funding from CureDuchenne Ventures, a subsidiary of the nonprofit Duchenne Muscular Dystrophy (DMD) advocacy group, CureDuchenne. This funding is aimed at further developing gene editing technologies, including CRISPR/Cas9, to potentially offer a curative therapy for Duchenne Muscular Dystrophy, a severe […]
